Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07371585 |
| Title | Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (TOP-REAL) |
| Acronym | TOP-REAL |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | SOLTI Breast Cancer Research Group |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | FRA | ESP | DEU |